SCHEMBL844904

SCHEMBL844904

CCOC(=O)c1c(C)cc2nc(C)n(-c3ccccc3S(=O)(=O)NC)c(=O)c2c1C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.72
CNR2 P34972 1/20 0.72
ALOX15 P16050 1/20 0.39
THRB P10828 1/20 0.38
TSHR P16473 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 3/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
KMT2A Q03164 2/20 0.35
ADORA1 P30542 1/20 0.35
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE1C Q14123 1/20 0.35
PDE3A Q14432 1/20 0.35
ATM Q13315 1/20 0.35
HPD P32754 1/20 0.35
NPC1 O15118 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844571 0.90 CNR1 (0.79) CNR1CNR2THRBTSHRKDM4E
SCHEMBL844509 0.88 CNR1 (0.58) CNR1CNR2ALOX15TSHRKDM4E
SCHEMBL844506 0.88 CNR1 (0.56) CNR1CNR2TSHRLMNAALDH1A1
SCHEMBL844174 0.86 CNR1 (0.87) CNR1CNR2THRBTSHRKDM4E
SCHEMBL844516 0.86 CNR1 (0.75) CNR1CNR2THRBTSHRKDM4E
SCHEMBL11374217 0.85 CNR1 (0.53) CNR1CNR2ALOX15THRBTSHR
SCHEMBL6681525 0.85 CNR1 (0.65) CNR1CNR2THRBTSHRKDM4E
Hydrochloric Acid SCHEMBL844735 0.85 CNR1 (0.86) CNR1CNR2THRBTSHRKDM4E
SCHEMBL844485 0.85 CNR1 (0.75) CNR1CNR2ALOX15THRBTSHR
SCHEMBL17692331 0.85 CNR1 (0.90) CNR1CNR2THRBTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8552015-B2 Quinazolinone derivatives and their use as CB agonists NOVARTIS AG (CH) 2013-10-08 US disclosed
EP-1472234-B1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS NOVARTIS AG (CH) 2012-03-28 EP disclosed
EP-2319839-A1 Quinazolinone derivatives and their use as CB agonists Novartis AG (CH) 2011-05-11 EP disclosed
US-20070265285-A1 Quinazolinone derivatives and their use as CB agonists NOVARTIS AG (CH) 2007-11-15 US disclosed
US-20050085493-A1 Quinazolinone derivatives and their use as cb agonists BRAIN CHRISTOPHER T (GB) 2005-04-21 US disclosed
EP-1472234-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS Novartis AG (CH) 2004-11-03 EP disclosed
WO-2003066603-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS NOVARTIS AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265285-A1 Quinazolinone derivatives and their use as CB agonists CNR1, ADRB1, ADRA1D CNR1 1/4885CNR2 8/4885ALOX15 3312/4885
US-20050085493-A1 Quinazolinone derivatives and their use as cb agonists CNR1, ADRB1, ADRA2B CNR1 1/4885CNR2 8/4885ALOX15 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.